Hospital
Morton Plant Hospital Association INC
Morton Plant Hospital Association INC was paid $7.34M by Medicaid between Jan 2018 and Dec 2024, across 136 billing codes. Its largest line is 99283, emergency room visit (moderate) — 23% of everything it billed.
33Billing provider infoMORTON PLANT HOSPITAL ASSOCIATION INC
NEW PORT RICHEY, FL 34652
NEW PORT RICHEY, FL 34652
33aNPI1437135811assigned 12/19/2005
33bProvider typePsychiatric Hospital Unit
28Total paid$7.34M
24GClaims362,419
24DCodes billed136
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in Florida
Rank by total paid#7 of 15
Median peer was paid$7.13M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 32,438 | $288K | |
| 2019 | 81,192 | $1.05M | |
| 2020 | 61,017 | $843K | |
| 2021 | 66,631 | $1.34M | |
| 2022 | 69,603 | $1.93M | |
| 2023 | 35,512 | $1.26M | |
| 2024incomplete | 16,026 | $629K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 20,618 | 18,774 | $1.72M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 21,139 | 18,231 | $1.17M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 9.9% | 5,285 | 4,677 | $729K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.2% | 10,567 | 8,534 | $674K |
| 70450 | Computed tomography, head or brain; without contrast material | 7.2% | 7,128 | 5,594 | $531K |
| 80053 | Comprehensive metabolic panel | 5.7% | 20,339 | 16,466 | $421K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 4.5% | 7,058 | 6,094 | $329K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.4% | 4,039 | 3,715 | $323K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.9% | 7,380 | 5,595 | $137K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.5% | 970 | 841 | $113K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.2% | 2,175 | 1,556 | $89K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.2% | 1,219 | 1,105 | $88K |
124 more codes
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.1% | 977 | $84K |
| 87631 | 1.0% | 1,803 | $75K | |
| 81025 | <1% | 5,086 | $61K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,327 | $60K |
| 36415 | Collection of venous blood by venipuncture | <1% | 25,747 | $56K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 1,987 | $54K |
| G0378 | Hospital observation service, per hour | <1% | 7,460 | $49K |
| 71045 | Radiologic examination, chest; single view | <1% | 15,270 | $37K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,989 | $37K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,170 | $33K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,046 | $28K |
| 82948 | <1% | 6,396 | $26K | |
| 73610 | <1% | 700 | $23K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 659 | $21K |
| 73562 | <1% | 981 | $20K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,442 | $19K |
| 73110 | <1% | 505 | $19K | |
| 73630 | <1% | 804 | $19K | |
| 73130 | <1% | 636 | $19K | |
| 81003 | <1% | 19,577 | $18K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,121 | $17K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,298 | $17K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,805 | $17K |
| 72100 | <1% | 1,378 | $14K | |
| 84484 | <1% | 12,010 | $13K | |
| 73030 | <1% | 788 | $12K | |
| 84703 | <1% | 3,818 | $11K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 565 | $11K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 28,048 | $10K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,975 | $10K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 892 | $10K |
| 80047 | <1% | 1,494 | $9K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 15,468 | $8K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 70 | $7K |
| 93971 | <1% | 643 | $7K | |
| 70486 | <1% | 202 | $7K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 459 | $6K |
| 83880 | <1% | 3,388 | $4K | |
| A9270 | Non-covered item or service | <1% | 1,807 | $4K |
| 85610 | <1% | 5,314 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,096 | $3K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,461 | $3K |
| 73502 | <1% | 216 | $2K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 72 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,975 | $2K |
| 85730 | <1% | 3,686 | $2K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 230 | $2K |
| 83735 | <1% | 4,487 | $2K | |
| 87040 | <1% | 1,953 | $2K | |
| 84702 | <1% | 1,016 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 639 | $2K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 79 | $2K |
| 80076 | <1% | 74 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,368 | $2K |
| 82330 | <1% | 2,397 | $1K | |
| 83690 | <1% | 6,044 | $1K | |
| 97161 | <1% | 15 | $1K | |
| 81001 | <1% | 420 | $1K | |
| 73080 | <1% | 24 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 537 | $1K |
| 87077 | <1% | 1,615 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,277 | $1K |
| 12001 | <1% | 102 | $1K | |
| 93970 | <1% | 56 | $966.20 | |
| 76801 | <1% | 405 | $950.13 | |
| 80061 | Lipid panel | <1% | 1,293 | $905.25 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 629 | $889.49 |
| 84145 | <1% | 467 | $889.15 | |
| 87186 | <1% | 1,365 | $849.23 | |
| 83605 | <1% | 1,170 | $827.86 | |
| 90715 | <1% | 597 | $662.32 | |
| 86900 | <1% | 685 | $645.01 | |
| 85380 | <1% | 1,141 | $632.66 | |
| 12011 | <1% | 39 | $607.59 | |
| 85027 | <1% | 1,996 | $569.65 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,818 | $506.57 |
| 76830 | Ultrasound, transvaginal | <1% | 299 | $492.01 |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 17 | $486.90 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,348 | $416.54 |
| 97162 | <1% | 60 | $323.03 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 368 | $257.69 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 720 | $220.70 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 653 | $219.96 |
| 72072 | <1% | 13 | $209.16 | |
| 74018 | <1% | 36 | $189.95 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 313 | $123.41 |
| 90791 | Psychiatric diagnostic evaluation | <1% | 17 | $123.29 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 221 | $123.29 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,023 | $114.28 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 437 | $110.33 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 288 | $110.24 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 910 | $93.07 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 914 | $88.51 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 580 | $73.34 |
| 87430 | <1% | 90 | $69.36 | |
| 86140 | <1% | 436 | $67.61 | |
| 29125 | <1% | 152 | $60.99 | |
| 87400 | <1% | 30 | $55.86 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 47 | $43.64 |
| 86901 | <1% | 683 | $41.84 | |
| 87641 | <1% | 13 | $31.58 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 27 | $8.44 |
| 84100 | <1% | 71 | $6.66 | |
| 82150 | <1% | 15 | $3.88 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 573 | $1.30 |
| 73090 | <1% | 13 | $1.16 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 585 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 445 | $0.00 |
| 82140 | 0% | 45 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 18 | $0.00 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 255 | $0.00 |
| 87660 | 0% | 129 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 19 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 18 | $0.00 |
| 82010 | 0% | 12 | $0.00 | |
| J1815 | Injection, insulin, per 5 units | 0% | 1,296 | $0.00 |
| 87510 | 0% | 129 | $0.00 | |
| 82077 | 0% | 179 | $0.00 | |
| 87480 | 0% | 129 | $0.00 | |
| 82550 | 0% | 182 | $0.00 | |
| 86850 | 0% | 67 | $0.00 | |
| 85652 | 0% | 14 | $0.00 | |
| 96376 | 0% | 25 | $0.00 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 39 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTREMONTI, CARL (CFO, BAYCARE HOSPITAL DIVISION)
| Provider | Location | Paid |
|---|---|---|
| Trustees of Mease Hospital INC | Clearwater, FL | $9.19M |
| Trustees of Mease Hospital INC | Dunedin, FL | $2.90M |
| Behavioral Health Management Services, INC. | Tampa, FL | $1.18M |
| Behavioral Health Management Services, INC. | Clearwater, FL | $698K |
| Morton Plant Hospital Association, INC | Belleair, FL | $582.59 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.